Devyser Diagnostics AB (DVYSR) - Total Assets
Based on the latest financial reports, Devyser Diagnostics AB (DVYSR) holds total assets worth Skr470.10 Million SEK (≈ $50.59 Million USD) as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Devyser Diagnostics AB - Total Assets Trend (2018–2025)
This chart illustrates how Devyser Diagnostics AB's total assets have evolved over time, based on quarterly financial data. Also see Devyser Diagnostics AB stock valuation for the company's overall valuation and market capitalisation.
Devyser Diagnostics AB - Asset Composition Analysis
Current Asset Composition (December 2025)
Devyser Diagnostics AB's total assets of Skr470.10 Million consist of 43.5% current assets and 56.5% non-current assets. Review DVYSR liabilities breakdown to assess the company's total debt and financial obligations.
| Asset Category | Amount (SEK) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Skr0.00 | 16.5% |
| Accounts Receivable | Skr67.00 Million | 14.3% |
| Inventory | Skr37.00 Million | 7.9% |
| Property, Plant & Equipment | Skr0.00 | 0.0% |
| Intangible Assets | Skr153.90 Million | 32.8% |
| Goodwill | Skr6.60 Million | 1.4% |
Asset Composition Trend (2018–2025)
This chart illustrates how Devyser Diagnostics AB's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See Devyser Diagnostics AB stock quote for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Devyser Diagnostics AB's current assets represent 43.5% of total assets in 2025, a decrease from 57.7% in 2018.
- Cash Position: Cash and equivalents constituted 16.5% of total assets in 2025, up from 15.6% in 2018.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 33.0% of total assets, an increase from 0.0% in 2018.
- Asset Diversification: The largest asset category is intangible assets at 32.8% of total assets.
Devyser Diagnostics AB Competitors by Total Assets
Key competitors of Devyser Diagnostics AB based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Medtronic plc
SA:MDTC34
|
Brazil | R$93.03 Billion |
|
Demant A/S
CO:DEMANT
|
Denmark | Dkr39.07 Billion |
|
Jiangsu Yuyue Medical Equipment & Supply Co Ltd
SHE:002223
|
China | CN¥16.89 Billion |
|
Jafron Biomedical Co Ltd
SHE:300529
|
China | CN¥5.20 Billion |
|
Sinocare Inc
SHE:300298
|
China | CN¥6.25 Billion |
|
Emvision Medical Devices Ltd
AU:EMV
|
Australia | AU$24.94 Million |
|
Theradiag SA
PA:ALTHE
|
France | €11.55 Million |
|
Biosynex
PA:ALBIO
|
France | €149.44 Million |
Devyser Diagnostics AB - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.90 | 2.97 | 14.02 |
| Quick Ratio | 2.29 | 2.48 | 13.79 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | Skr130.60 Million | Skr145.50 Million | Skr383.23 Million |
Devyser Diagnostics AB - Advanced Valuation Insights
This section examines the relationship between Devyser Diagnostics AB's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 4.56 |
| Latest Market Cap to Assets Ratio | 0.21 |
| Asset Growth Rate (YoY) | -0.9% |
| Total Assets | Skr469.70 Million |
| Market Capitalization | $99.01 Million USD |
Valuation Analysis
Below Book Valuation: The market values Devyser Diagnostics AB's assets below their book value (0.21x), which may indicate investor concerns about asset quality or future growth.
Slight Asset Contraction: Devyser Diagnostics AB's assets decreased by 0.9% over the past year, which may reflect streamlining or optimization of resources.
Annual Total Assets for Devyser Diagnostics AB (2018–2025)
The table below shows the annual total assets of Devyser Diagnostics AB from 2018 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | Skr469.70 Million ≈ $50.55 Million |
-0.87% |
| 2024-12-31 | Skr473.80 Million ≈ $50.99 Million |
-7.12% |
| 2023-12-31 | Skr510.10 Million ≈ $54.89 Million |
+1.89% |
| 2022-12-31 | Skr500.63 Million ≈ $53.88 Million |
+9.58% |
| 2021-12-31 | Skr456.87 Million ≈ $49.17 Million |
+514.43% |
| 2020-12-31 | Skr74.36 Million ≈ $8.00 Million |
+0.89% |
| 2019-12-31 | Skr73.70 Million ≈ $7.93 Million |
+52.84% |
| 2018-12-31 | Skr48.22 Million ≈ $5.19 Million |
-- |
About Devyser Diagnostics AB
Devyser Diagnostics AB (publ) provides diagnostic kits and advanced analysis services for clinical genetics and post-transplantation laboratories in Sweden, rest of Europe, the Middle East, and Africa. It offers kits and reagents, such as post-transplantation, thalassemia, fetal RHD screening NIPT, Cystic fibrosis cardiovascular diseases, male infertility, rapid aneuploidy analysis, accessories, … Read more